Sugi Predict

Sugi Predict / Compounds / SCHEMBL30160457

SCHEMBL30160457

SCHEMBL30160457

Cc1cc(C2CN(c3cc4nc(C)c(C)cc4c(-c4ccc(Cl)cc4F)n3)CCO2)ccn1

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ PDE10A Q9Y233 4/20 0.37
▸ PDE2A O00408 3/20 0.35
▸ GSK3B P49841 5/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ GRM2 Q14416 2/20 0.33
▸ EIF2AK4 Q9P2K8 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ PIK3CA P42336 1/20 0.31
▸ PIK3CB P42338 1/20 0.31
▸ CRHR1 P34998 1/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ PKM P14618 1/20 0.31
▸ HSD17B10 Q99714 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24009481 1.00 PDE10A (0.37) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL29978032 0.92 PDE10A (0.38) PDE10AGSK3BCYP1A2CYP2D6PIK3CA
SCHEMBL24009480 0.92 PDE10A (0.38) PDE10AGSK3BCYP1A2CYP2D6PIK3CA
SCHEMBL30160469 0.90 PDE10A (0.38) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL24010403 0.90 PDE10A (0.38) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL24009715 0.90 PDE10A (0.38) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL24010824 0.90 PDE10A (0.38) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL30160532 0.90 PDE10A (0.38) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL24010825 0.86 P2RX7 (0.35) PDE10APDE2AGSK3BMEN1NPC1
SCHEMBL24010865 0.86 P2RX7 (0.35) PDE10APDE2AGSK3BMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12428425-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2025-09-30 — — US disclosed
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. (US) 2024-09-19 — — US disclosed
US-20240182477-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE VIGIL NEUROSCIENCE, INC. 2024-06-06 — — US disclosed
US-11912711-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2024-02-27 — — US disclosed
US-11884675-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2024-01-30 — — US disclosed
US-20230295170-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE AMGEN INC. 2023-09-21 — — US disclosed
US-20230295169-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE AMGEN INC. 2023-09-21 — — US disclosed
US-11608344-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use AMGEN INC. (US) 2023-03-21 — — US disclosed
US-20230002390-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE AMGEN INC. 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12428425-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-20230002390-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-20240309003-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-20240182477-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-11912711-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-11608344-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-20230295169-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-20230295170-A1 HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885
US-11884675-B2 Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use MSR1, FPR2, CD14 PDE10A 3729/4885PDE2A 2161/4885GSK3B 3421/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback